Candel Therapeutics, Inc. (CADL) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Candel Therapeutics, Inc. (CADL) closed at USD 9.07 on 2026-10-14, a change of +62 % over the past year, with a market capitalization of USD 681.78M.

Candel Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Candel Therapeutics, Inc. key figures

Previous close

USD 9.07 (2026-10-14)

1-year change

+62 %

Market cap

USD 681.78M

Enterprise value

USD 529.73M

P/E ratio (trailing)

-6.23

P/E ratio (forward)

-14.26

EPS (trailing)

-1.43

EPS (forward)

-0.63

PEG ratio

n/a

Price to book

5.38

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

11.02

Employees

55

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Candel Therapeutics, Inc.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Candel Therapeutics, Inc. and compare it with other stocks.